Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

miR-23a impairs bone differentiation in osteosarcoma via down-regulation of GJA1.

Gindin Y, Jiang Y, Francis P, Walker RL, Abaan OD, Zhu YJ, Meltzer PS.

Front Genet. 2015 Jul 2;6:233. doi: 10.3389/fgene.2015.00233. eCollection 2015.

2.

NCI-60 whole exome sequencing and pharmacological CellMiner analyses.

Reinhold WC, Varma S, Sousa F, Sunshine M, Abaan OD, Davis SR, Reinhold SW, Kohn KW, Morris J, Meltzer PS, Doroshow JH, Pommier Y.

PLoS One. 2014 Jul 17;9(7):e101670. doi: 10.1371/journal.pone.0101670. eCollection 2014.

3.

104th American Association For Cancer Research (AACR) annual meeting; breakthroughs in science and technology changing cancer care.

Abaan OD, Bilke S.

ACS Chem Biol. 2013;8(6):1097-100. doi: 10.1021/cb400366r. No abstract available.

PMID:
24491168
4.

Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel.

Gao R, Das BB, Chatterjee R, Abaan OD, Agama K, Matuo R, Vinson C, Meltzer PS, Pommier Y.

DNA Repair (Amst). 2014 Jan;13:1-9. doi: 10.1016/j.dnarep.2013.09.001. Epub 2013 Dec 16.

5.

High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.

Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.

Nat Genet. 2014 Jan;46(1):8-10. doi: 10.1038/ng.2828. Epub 2013 Nov 17.

6.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS.

Cancer Res. 2013 Jul 15;73(14):4372-82. doi: 10.1158/0008-5472.CAN-12-3342. Epub 2013 Jul 15.

7.

Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.

Abaan OD, Hendriks W, Uren A, Toretsky JA, Erkizan HV.

Exp Cell Res. 2013 Jan 1;319(1):1-11. doi: 10.1016/j.yexcr.2012.09.003. Epub 2012 Sep 24.

8.

CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly JW Jr, Monks A, Shoemaker RH, Abaan OD, Davis SR, Meltzer PS, Doroshow JH, Pommier Y.

Oncogene. 2012 Jan 26;31(4):403-18. doi: 10.1038/onc.2011.283. Epub 2011 Jul 18. Erratum in: Oncogene. 2012 Jan 26;31(4):535-6.

PMID:
21765476
9.

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.

Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA.

Nat Med. 2009 Jul;15(7):750-6. doi: 10.1038/nm.1983. Epub 2009 Jul 5.

10.

Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients.

Abaan OD, Mutlu PK, Baran Y, Atalay C, Gunduz U.

Cancer Invest. 2009 Feb;27(2):201-5. doi: 10.1080/07357900802173562.

PMID:
19235593
11.

PTPL1: a large phosphatase with a split personality.

Abaan OD, Toretsky JA.

Cancer Metastasis Rev. 2008 Jun;27(2):205-14. doi: 10.1007/s10555-008-9114-2. Review.

12.

Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.

Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, Rice AM, Lee SB, Uren A.

Cancer Res. 2006 Jun 1;66(11):5574-81.

13.

PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.

Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA.

Oncogene. 2005 Apr 14;24(16):2715-22.

PMID:
15782144

Supplemental Content

Loading ...
Support Center